Puma Biotechnology, Inc.

NASDAQ: PBYI
$2.78
-$0.07 (-2.5%)
Closing price July 1, 2022
Puma Biotechnology, Inc. (NASDAQ: PBYI) saw its shares touch a multiyear high on Tuesday after the firm reported a key approval by the U.S. Food and Drug Administration (FDA). Specifically, the...
Stocks were indicated marginally lower on Tuesday, but the major equity indexes remain just under all-time highs. The bull market may now be well over eight years old, but investors keep proving that...
The top analyst upgrades, downgrades and other research calls from Friday include Boeing, Costco, Intel, KeyCorp, NVIDIA, PayPal and Snap.
The Annual Meeting for the American Society of Clinical Oncology (ASCO) is currently underway in Chicago, and the health care sector is on the move.
Now that the U.S. presidential election is over and markets have recovered to their highs, there are still some stocks holding back the markets from breaking even higher.
Some companies are hitting lows and creating huge shareholder losses while the market is just below all-time highs but still struggling. These are the same companies holding back the market and...
Puma Biotechnology, Inc. (NYSE: PBYI) recently filed with the U.S. Securities and Exchange Commission (SEC) for a secondary offering. No pricing details were announced, except that the offering would...
The SEC has charged the former senior director of regulatory affairs for Puma Biotechnology with insider trading ahead of the company’s news announcements about its drug to treat breast cancer.
The week of September 23 brought numerous analyst upgrades and downgrades in the biotech and biohealth space.
Puma Biotechnology posted strong gains over the course of this past week, which began with some positive news from the FDA and continued with a huge analyst call.
Puma Biotechnology Inc. (NYSE: PBYI) has made solid gains over the course of this week, starting with some positive news from the U.S. Food and Drug Administration (FDA), but now shares are being...
The top analyst upgrades, downgrades and initiations seen on Thursday morning include Alibaba, Amazon, Bed Beth & Beyond, Puma Biotechnology and SeaWorld.
Shares of Puma Biotechnology had a strong gain in Tuesday’s session following some positive news from the FDA on the company's breast cancer treatment.
Puma Biotechnology watched its shares make a handy gain on Friday morning after the firm released updated results from its late-stage breast cancer trial.
The American Society of Clinical Oncology (ASCO) is gearing up for its annual meeting. At this meeting, cancer drug developers will share the results from their most recent drug trials.